Version 1
: Received: 2 September 2020 / Approved: 7 September 2020 / Online: 7 September 2020 (12:29:06 CEST)
Version 2
: Received: 26 October 2020 / Approved: 27 October 2020 / Online: 27 October 2020 (11:25:32 CET)
How to cite:
Klasse, P.; Nixon, D.F.; Moore, J.P. Immunogenicity of Clinically Relevant SARS-CoV-2 Vaccines in Non-human Primates and Humans. Preprints.org2020, 2020090166
Klasse, P.; Nixon, D.F.; Moore, J.P. Immunogenicity of Clinically Relevant SARS-CoV-2 Vaccines in Non-human Primates and Humans. Preprints.org 2020, 2020090166
Cite as:
Klasse, P.; Nixon, D.F.; Moore, J.P. Immunogenicity of Clinically Relevant SARS-CoV-2 Vaccines in Non-human Primates and Humans. Preprints.org2020, 2020090166
Klasse, P.; Nixon, D.F.; Moore, J.P. Immunogenicity of Clinically Relevant SARS-CoV-2 Vaccines in Non-human Primates and Humans. Preprints.org 2020, 2020090166
Abstract
Multiple preventive vaccines are being developed to counter the COVID-19 pandemic. The leading candidates have now been evaluated in non-human primates (NHPs) and human Phase 1 and/or Phase 2 clinical trials. Several vaccines have already advanced into Phase 3 efficacy trials, while others will do so before the end of 2020. Here, we summarize what is known of the antibody and T-cell immunogenicity of these vaccines in NHPs and humans. To the extent possible, we compare how the vaccines have performed, taking into account the use of different assays to assess immunogenicity and inconsistencies in how the resulting data are presented. We also summarize the outcome of SARS-CoV-2 challenge experiments in immunized macaques, while noting variations in the protocols used, including but not limited to the virus challenge doses.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
